...be gel adaptors, 24 glass tubes (1.5 mm ID, 180 mm... II xi cell and PROTEAN II XL wide-format cell off...ions,* including SDS-PAGE, first- and second-dimen... gradient PAGE as well as high-resolution agarose ...
SVT3-2 Diverter Valve from Bio-Rad
PROTEAN II XL Cell, wide format from Bio-Rad
PROTEAN II xi Cell, 20 cm, without spacers and combs from Bio-Rad
Biology Products:...ss announces the latest edition of an essential ...pidly changing fields of clinical medicine. Coveri...nosis, treatment, and prevention, Clinical Virolo...ls about all the medically relevant aspects of thi...tly one of the most dynamic areas of clinical medi...
...helle, NY, March 17, 2009While the Bernard Madoff ...undation, a major benefactor for life science rese...from the scandal as a minor consequence in the lar... & Biotechnology News (GEN). They look at the Mad... global financial environment that has been rocked...
... human papilloma virus (HPV)-infections can lead t...-stage to cervical cancer. Surgical treatment of t... birth in subsequent pregnancies. As the HPV-vacci...ay therefore reduce the number of preterm births. ...of HPV-vaccination. , Cervical cancer developmen...
Other Biology News:New edition available for essential virology reference 2GEN reports on Madoff scandal's impact on the life sciences 2HPV vaccine may prevent preterm births 2(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5